Diabetic cardiomyopathy (DCM) as an imperative menace to health takes place without or
with coexistence of vascular diseases. Even though numerous pathological mechanisms are
accountable for DCM have been estimated, oxidative stress is extensively well thought-out as
a foremost key cause for the pathogenesis of the DCM. In this review we focused on role of
bioactive compounds using different sources like plant and marine products in
cardiomyopathy. Natural products and their related constituents have traditionally been
implausible as a resource of curative agents. In last few decades, studies into natural products
in the pharma field has condensed, still to pay to problems such as the requirement of
compatibility of conventional natural product extract libraries with high‒throughput
selection. From ancient time documented that natural product structures have the
characteristics of high chemical variety, biochemical specificity and other molecular
properties that make them favorable as direct structures for drug invention, and which
provide to distinguish them from libraries of combinatorial and synthetic compounds.
Consequently, the aim of this review is to provide an overview on the recent progress and
development in the bio-active compounds in DCM and also to focus on the cellular
mechanisms underlying cardiomyocyte dysfunction for their therapeutic targets.
Keywords: Diabetic cardiomyopathy, hyperglycemia, insulin pathway, endothelial
dysfunction, plant products, bioactive compounds.
Rights & PermissionsPrintExport